• LAST PRICE
    14.7800
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.0676%)
  • Bid / Lots
    14.6500/ 1
  • Ask / Lots
    14.8200/ 4
  • Open / Previous Close
    14.7800 / 14.7900
  • Day Range
    Low 14.7100
    High 14.8500
  • 52 Week Range
    Low 10.7501
    High 18.4400
  • Volume
    3,107
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTRDA
Entrada Therapeutics Inc
499.3M
23.6x
---
United StatesHRTX
Heron Therapeutics Inc
515.2M
-5.6x
---
United StatesTVTX
Travere Therapeutics Inc
540.5M
-1.3x
---
United StatesCDMO
Avid Bioservices Inc
472.3M
-25.1x
---
United StatesKMDA
Kamada Ltd
290.8M
19.3x
-22.48%
United StatesALEC
Alector Inc
410.6M
-3.0x
---
As of 2024-06-20

Company Information

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Contact Information

Headquarters
One Design Center Place, Suite 17-500BOSTON, MA, United States 02210
Phone
857-305-1825
Fax
302-655-5049

Executives

Independent Chairman of the Board
Kush Parmar
President, Chief Operating Officer
Nathan Dowden
Chief Executive Officer, Director
Dipal Doshi
Chief Financial Officer, Treasurer
Kory Wentworth
Chief Scientific Officer
Natarajan Sethuraman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$499.3M
Revenue (TTM)
$162.9M
Shares Outstanding
33.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.63
Book Value
$7.25
P/E Ratio
23.6x
Price/Sales (TTM)
3.1
Price/Cash Flow (TTM)
18.6x
Operating Margin
14.57%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.